Celltrion (KRX:068270) biosimilar Stekla, a copy of Janssen's ustekinumab for autoimmune disease, held 16.2% of the US market by volume in July 2026, up from 14.9% in June, data-tracking firm IQVIA reported Wednesday. The Seoul-based company has grown share steadily since US launch in 2024, reflecting tailored physician outreach and favorable US insurance reimbursement terms.
Stekla competes in the ustekinumab biosimilar market against originals and other generics. Market penetration typically peaks three to four years post-launch as prescriber familiarity spreads. Celltrion's July gain suggests physician adoption is accelerating rather than plateauing.
Celltrion's market capitalisation was ₩43.5 trillion at Thursday's close. The company manufactures biologics and biosimilars at facilities in Incheon and Songdo. US biosimilar revenue comes through distribution partners rather than direct sales. First-half 2026 operating income of ₩374bn reflected contract manufacturing delays rather than biosimilar volume.
kstock reads DART every morning and writes up what moved — the contract, the buyback, the number that does not add up. The daily post and a Saturday roundup, by email.
| Symbol | Last Price |
|---|---|
| 068270Celltrion, Inc. | ₩188,100 +0.5% |